论文部分内容阅读
目的评估不同严重程度及控制水平的支气管哮喘(哮喘)患儿血清超敏C-反应蛋白(hs-CRP)水平,探讨其临床价值。方法选取本院儿科门诊和住院的儿童哮喘患者80例,分为2组:40例为非激素治疗组(非激素组),40例为吸入性激素治疗组(激素组)。测定患儿hs-CRP水平和经校正年龄和性别的第1秒用力呼气量(FEV1)%的预计值,并进行诱导痰细胞学检查。同时纳入80例年龄和性别匹配的健康儿童作为健康对照组。结果哮喘患儿血清hs-CRP水平显著高于健康对照组,非激素组血清hs-CRP水平显著高于激素组。激素组与非激素组患儿血清hs-CRP水平均与FEV1%预计值呈负相关。结论尽管肺功能检查和临床分类作为哮喘分级的金标准,但hs-CRP可作为评估哮喘严重程度及控制水平的新指标,其可在哮喘患儿中用来间接监测呼吸道炎症、疾病严重性和对激素的治疗反应。
Objective To evaluate the serum levels of hs-CRP in asthmatic children with different severity and control levels and to evaluate its clinical value. Methods Eighty children with pediatric outpatients and hospitalized asthmatic children were enrolled in this study. They were divided into two groups: 40 in non-hormonal treatment group and 40 in inhaled steroid treatment group. Estimated hs-CRP levels in children and predicted first-second forced expiratory volume (FEV1)% of corrected age and sex were measured and induced sputum cytology was performed. At the same time, 80 healthy children of age and sex matched as healthy control group. Results Serum hs-CRP levels in asthmatic children were significantly higher than those in healthy controls, and serum hs-CRP levels in non-hormonal groups were significantly higher than those in the hormone group. The levels of serum hs-CRP in hormone group and non-hormone group were negatively correlated with the predicted value of FEV1%. Conclusions Although lung function tests and clinical classification are the gold standard for asthma classification, hs-CRP can be used as a new indicator for assessing the severity and control of asthma, which can be used in children with asthma to indirectly monitor respiratory inflammation, disease severity, Response to hormone therapy.